| Literature DB >> 36053638 |
Anouk W J Scholten1,2, Zhuozhao Zhan3, Hendrik J Niemarkt4, Marieke Vervoorn4, Ruud W van Leuteren5,2, Frans H de Jongh5,6, Anton H van Kaam5,2, Edwin R van den Heuvel3, G Jeroen Hutten5,2.
Abstract
INTRODUCTION: Cardiorespiratory monitoring is used in the neonatal intensive care unit (NICU) to assess the clinical status of newborn infants and detect critical deteriorations in cardiorespiratory function. Currently, heart rate (HR) is monitored by electrocardiography (ECG) and respiration by chest impedance (CI). Disadvantages of current monitoring techniques are usage of wired adhesive electrodes which may damage the skin and hinder care. The Bambi® belt is a wireless and non-adhesive alternative that enables cardiorespiratory monitoring by measuring electrical activity of the diaphragm via transcutaneous electromyography. A previous study showed feasibility of the Bambi® belt and this study compares the belt performance to ECG and CI. METHODS AND ANALYSIS: This multicentre non-inferiority paired study will be performed in the NICU of the Máxima Medical Center (MMC) in Veldhoven and the Emma Children's Hospital, Amsterdam University Medical Centre (AmsterdamUMC) in Amsterdam, The Netherlands. 39 infants in different postmenstrual age groups (minimally 10 infants<30 weeks, between 30-32 weeks and >32 weeks) will be recruited. These infants will be monitored with the Bambi® belt in addition to standard ECG and CI for 24 hours. The primary outcome is the HR, studied with three criteria: (1) the limits of agreement of the HR measurements in terms of the second-to-second difference in the HR between the belt and standard ECG, (2) the detection of cardiac events consisting of bradycardia and tachycardia and (3) the quality of HR-monitoring. The secondary outcome is the respiratory rate (RR), studied with the criteria (1) agreement in RR-trend monitoring, (2) apnoea and tachypnoea detection and (3) reliable registrations. ETHICS AND DISSEMINATION: This protocol was approved by the Medical Ethical Committee of the MMC and the Central Committee for Human Research. The MMC started patient recruitment in July and the AmsterdamUMC in August 2021. The results will be presented at conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NL9480. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: Neonatology; Technology
Mesh:
Substances:
Year: 2022 PMID: 36053638 PMCID: PMC9185582 DOI: 10.1136/bmjpo-2022-001430
Source DB: PubMed Journal: BMJ Paediatr Open ISSN: 2399-9772
The non-inferiority/equivalence margins for the primary and secondary outcomes
| Endpoints | Prespecified margins* |
| LOA of second-to-second HR differences | ±8 bpm |
| LOA of RR-trend differences | ±15 bpm |
| Sensitivity of brady-/tachycardia detection | 90%† |
| PPV of brady-/tachycardia detection | 90%† |
| Sensitivity of apnoea/tachypnoea detection | 70% |
| PPV of apnoea/tachypnoea alarms | 0%–100%‡ |
| Data loss percentage | 5% |
| Robust data percentage (HR) | 90% |
| Robust data percentage (RR) | 70% |
Data loss is defined as the percentage of data with ‘Leads off’ or ‘Bluetooth Loss Error’ in the belt.
*The prespecified margins are compared to confidence intervals with corresponding confidence levels (see SAP for more details).
†Note: all missed bradycardias are checked for clinical relevance by two independent experts.
‡Since the reference devices for apnoea detection in the clinical practice are the peripheral oxygen saturation (SpO2) and electrocardiogram instead of the respiration signal and the performance for chest impedance to detect tachypnoea is unsatisfactory due to the presence of cardiac interference, all values for PPV for apnoea/tachypnoea are acceptable. Interpretations will be made based on the results.
HR, heart rate; LOA, limits of agreement; PPV, positive predictive value; RR, respiratory rate; SAP, statistical analysis plan.
Figure 1The measurement setup. The adhesive electrodes used for standard cardiorespiratory monitoring are attached at the original location, visualised by the three grey dots. The diaphragm activity measured with the Bambi® belt is wirelessly transmitted with the sensor module to the receiver module where the data is processed to obtain an electrocardiogram and respiration waveform (and heart rate and respiratory rate). These data and the data measured with the patient monitor are transported to a personal bedside computer with Polybench software to synchronise and record these signals.
Figure 2The Bambi® belt is a wireless non-adhesive belt designed for cardiorespiratory monitoring of (pre)term infants. The three dry electrodes2 measure electrical activity of the diaphragm via transcutaneous electromyography. These data are wirelessly transmitted with the sensor module1 to a receiver module that processes the diaphragm activity to obtain the electrocardiogram, respiration signal, heart rate and respiratory rate.